Home » Topics » BioWorld Science

BioWorld Science
RSS

Columbia seeks FDA approval of Crinone

Aug. 9, 1996

Aldose reductase inhibitors disclosed by Nippon Zoki

Aug. 9, 1996

FDA approves phaseI/II trial of VivoRx's BetaRx-P

Aug. 9, 1996

Canadian researchers report GLP-2's potential as digestive disease treatment

Aug. 9, 1996

Astra reports gastrin secretion inhibitors

Aug. 9, 1996

Bicyclic fibrinogen antagonists described by SmithKline Beecham

Aug. 9, 1996

Piperazine fibrinogen antagonists from Thomae

Aug. 9, 1996

RO-11 demonstrates efficacy in phase III as DVT prevention agent

Aug. 9, 1996

Thrombin inhibitors inhelabo's pipeline

Aug. 9, 1996

RPR's enoxaparin reduces risk of DVT following hip replacement

Aug. 9, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.